Study of Out of Specification for Tisagenlecleucel
- Conditions
- B-cell Acute Lymphoblastic LeukemiaDiffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2019-09-18
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT04094311
- Locations
- π―π΅
Novartis Investigative Site, Wakayama, Japan
Managed Access Program (MAP) to Provide Access to Alpelisib (BYL719) for Patients With PIK3CA-Related Overgrowth Spectrum (PROS)
- Conditions
- PIK3CA-Related Overgrowth Spectrum (PROS)
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04085653
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
- Conditions
- Migraine HeadacheMigraineMigraine Disorders
- Interventions
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 701
- Registration Number
- NCT04084314
- Locations
- π©πͺ
Novartis Investigative Site, Wuerzburg, Germany
Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema
- First Posted Date
- 2019-09-06
- Last Posted Date
- 2021-03-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT04079231
Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 23
- Registration Number
- NCT04074590
- Locations
- πΈπ°
Novartis Investigative Site, Kosice, Slovakia
Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 974
- Registration Number
- NCT04072887
- Locations
- π¬π§
Novartis Investigative Site, London, United Kingdom
Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 86
- Registration Number
- NCT04072302
- Locations
- πΊπΈ
Novartis Investigative Site, Seattle, Washington, United States
Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT04066244
- Locations
- πΊπΈ
Yale University School of Medicine, New Haven, Connecticut, United States
πΊπΈMassachusetts General Hospital, Boston, Massachusetts, United States
πΈπͺNovartis Investigative Site, Stockholm, Sweden
Efficacy, Safety and Tolerability of the Combination of Tropifexor & Licogliflozin and Each Monotherapy, Compared With Placebo in Adult Patients With NASH and Liver Fibrosis.
- Conditions
- Non Alcoholic Steatohepatitis (NASH)
- Interventions
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 234
- Registration Number
- NCT04065841
- Locations
- πΊπΈ
Gut PC Digestive Health Specialist, Dothan, Alabama, United States
πΊπΈIntegrity Clinical Rsh LLC, Doral, Florida, United States
π¬π§Novartis Investigative Site, London, United Kingdom
Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis
- First Posted Date
- 2019-08-21
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT04064242
- Locations
- π¬π§
Novartis Investigative Site, London, United Kingdom
πΊπΈUniv of Florida College of Medicine x, Gainesville, Florida, United States
πΊπΈUniversity of Kansas Medical Center, Kansas City, Kansas, United States